Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.87 Increased by +104.44% | 1.43 Decreased by -39.16% |
| May 15, 23 | -1.34 Increased by +81.39% | -1.51 Increased by +11.26% |
| Mar 30, 23 | -0.92 Increased by +87.22% | -3.08 Increased by +70.13% |
| Nov 9, 22 | -2.40 Increased by +73.33% | -5.50 Increased by +56.36% |
| Aug 11, 22 | -19.60 Decreased by -104.17% | -7.50 Decreased by -161.33% |
| May 16, 22 | -7.20 Increased by +21.74% | -7.60 Increased by +5.26% |
| Mar 15, 22 | -7.20 Increased by +50.68% | -8.80 Increased by +18.18% |
| Nov 8, 21 | -9.00 Increased by +22.41% | -9.05 Increased by +0.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.26 M Increased by +96.68% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.15 M Increased by +47.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -110.78 M Decreased by -1.33 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -4.18 M Increased by +55.82% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -98.31 M Decreased by -859.04% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -7.94 M Increased by +17.89% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -7.76 M Increased by +49.60% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -9.45 M Increased by +23.26% | Decreased by N/A% Decreased by N/A% |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.